H.C. Wainwright raised the firm’s price target on Verona Pharma (VRNA) to $85 from $75 and keeps a Buy rating on the shares. The firm says the company’s sales continue to soundly beat its revenue forecasts. The commercialization of Verona’s sole marketed product, Ohtuvayre, “continues at a torrid pace,” the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRNA:
- Verona Pharma Reports Strong Q1 2025 Earnings
- Verona Pharma’s Earnings Call: O2VERE’s Success Fuels Optimism
- Verona Pharma reports Q1 EPS (2c), consensus (3c)
- Verona Pharma’s Promising Outlook: Buy Rating Backed by Strong Ohtuvayre Sales and Strategic Positioning
- Verona Pharma initiated with a Buy at TD Cowen